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Abstract: This article reviews the current knowledge base related to the pharmacological 
treatments for acute bronchiolitis. Bronchiolitis is a common lower respiratory illness affecting 
infants worldwide. The mainstays of therapy include airway support, supplemental oxygen, 
and support of ﬂ  uids and nutrition. Frequently tried pharmacological interventions, such as 
ribavirin, nebulized bronchodilators, and systemic corticosteroids, have not been proven to 
beneﬁ  t patients with bronchiolitis. Antibiotics do not improve the clinical course of patients 
with bronchiolitis, and should be used only in those patients with proven concurrent bacterial 
infection. Exogenous surfactant and heliox therapy also cannot be recommended for routine 
use, but surfactant replacement holds promise and should be further studied.
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Introduction
Acute bronchiolitis is the most common lower respiratory tract illness in infants and 
young children, and is usually the result of viral infection. Respiratory syncytial virus 
(RSV) is the most frequent infecting agent (Wright et al 1989). This disease is char-
acterized by inﬂ  ammation, edema, and necrosis of the small airway epithelium with 
associated bronchospasm and increased mucous production. Bronchiolitis is a seasonal 
illness with the highest incidence between December and March in the Northern 
Hemisphere. However, there is signiﬁ  cant regional variability in the timing and dura-
tion of RSV seasons throughout the US (Mullins et al 2003), and in tropical areas the 
virus is usually endemic and present in the community throughout the year.
Epidemiology
Acute bronchiolitis is a far reaching illness. Virtually all children have been infected 
with RSV by the age of 2 years, and nearly half of those will experience two infec-
tions (Glezen et al 1986). Of those infected, 40% will develop a lower respiratory 
tract infection (LRTI) (Bronchiolitis 2006). It is estimated that each year, as many 
as 126,000 infants are hospitalized in the US due to bronchiolitis (Shay et al 1999). 
While this represents a large burden, the numbers outside of the US are staggering. 
Worldwide, as many as 1/200 infants are hospitalized annually for treatment of  LRTI, 
with a mortality rate as high as 5% (Davies et al 1996). In the US, RSV-associated 
mortality has declined from 4500 deaths in 1985 (Shay et al 2001) to 390 deaths in 
1999 (Leader and Kohlhase 2003). The estimated annual cost of hospitalization for 
infants with bronchiolitis exceeds US $700 million (Stang et al 2001).
Etiology
Acute bronchiolitis is predominantly caused by viral infection, with RSV accounting 
for greater than 50% of cases. Other important viral causes include adenovirus, inﬂ  u-
enza virus, parainﬂ  uenza virus, human metapneumovirus, and rhinovirus. Mycoplasma 
pneumoniae may occasionally be associated with bronchiolitis.Therapeutics and Clinical Risk Management 2008:4(5) 896
Wright et al
RSV is extremely contagious, with a 98% attack rate for 
ﬁ  rst-time infection during epidemics. This decreases to a 
75% attack rate for second infections (Henderson et al 1979). 
Transmission generally requires close contact, with exposure 
of the nasal mucosa or conjunctiva to infected secretions (Hall 
et al 1981). Thus, well implemented contact isolation precau-
tions are effective in limiting spread of the infection.
Reinfection with RSV over an individual’s lifetime is 
common; however, the ﬁ  rst infection is generally the most 
severe and the most likely to involve the lower respiratory 
tract (Shay et al 1999). The second infection can also be quite 
severe, but after two RSV infections, the acquired immunity 
usually provides a signiﬁ  cant reduction in the severity of a 
third and subsequent infections (Henderson et al 1979). Pre-
maturely born children with chronic lung disease remain at 
risk for severe RSV infections for the ﬁ  rst two years of life, 
and many forms of immune deﬁ  cit and congenital heart dis-
ease represent a risk factor independent of age (MacDonald 
et al 1982; Hall et al 1986; Boyce et al 2000).
Pathophysiology
During the acute phase of bronchiolitis, the infecting virus 
precipitates an inﬂ  ammatory response that results in edema, 
inﬂ  ammatory cellular inﬁ  ltration, and sloughing of the lower 
airway epithelium. This leads to bronchiolar plugging and 
hyperinﬂ  ation, which is exacerbated by impaired ciliary 
clearance of mucous and cellular debris. After an early 
phase characterized by chemotaxis of polymorphonuclear 
leukocytes, the inﬂ  ammatory inﬁ  ltrates in infected airways 
become predominantly lympho-monocytic. In infants, the 
inﬂ  ammation is generally limited to the small airways, spar-
ing the alveoli (Simoes 1999), whereas later in life the infec-
tion is usually limited to the upper respiratory tract and large 
airways. The inﬂ  ammatory response to RSV appears to be 
ampliﬁ  ed and sustained by the peripheral nervous system via 
complex neuro-immune interactions primed by the virus.
In immunocompetent hosts, the infection with RSV is 
cleared within two weeks, whereas immunocompromised 
hosts can harbor and spread the virus for several months. 
Despite being a relatively short, self-limiting infection, RSV 
bronchiolitis is followed by chronic respiratory sequelae 
in a large proportion of children, particularly as recurrent 
episodes of wheezing that frequently lead to a diagnosis of 
asthma during the ﬁ  rst decade of life.
Clinical features
The incubation period for RSV ranges from 2 to 8 days. 
Infants develop signs and symptoms of a mild upper 
respiratory tract infection within one week of exposure to 
an infected individual. This progresses to increased work of 
breathing, cough, wheezing, and irritability. The respiratory 
distress may range from mild to severe with nasal ﬂ  aring, 
grunting, accessory muscle use and marked intercostal and 
subcostal retractions. Premature infants and newborns may 
present with decreased appetite, lethargy, and apnea after the 
upper respiratory tract infection prodrome.
Apnea is among the most common clinical manifesta-
tions of RSV infection in young infants, with an estimated 
incidence of 16%–25% (Sabogal et al 2005). A particularly 
high risk is associated with young age (<3 months) and 
prematurity. Interestingly, apnea can be the presenting sign 
of this infection preceding the onset of wheezing and other 
lower respiratory symptoms. This clinical observation and 
data obtained in animal models suggest that RSV can trigger 
apnea in as early as the nasal phase of the infection, before 
spreading to the lower airways. Because of its ability to 
interfere with ventilatory control, RSV infection has also 
been suggested as a precipitating factor in cases of sudden 
infant death.
Supportive care
The severity of bronchiolitis varies from mild to severe. 
Most infants endure a self-limited illness that can be treated 
in an outpatient setting, with close follow up to ensure that 
they have no respiratory distress, no supplemental oxygen 
requirement and remain well hydrated. Infants with moderate 
or severe disease characterized by poor feeding, tachypnea, 
nasal ﬂ  aring or supplemental oxygen requirement should be 
admitted to the hospital for more aggressive management and 
monitoring. Regardless of the setting in which the patient 
is treated, the mainstay of therapy remains supportive care, 
which includes respiratory support and adequate ﬂ  uid and 
nutrition management.
Children who are hypoxemic with oxygen satura-
tions 90% should receive warm, humidified oxygen 
(Bronchiolitis 2006). Nasal obstruction is a common prob-
lem, and given that young infants are obligate nose breathers, 
may result in a signiﬁ  cant increase in respiratory distress. Our 
experience has demonstrated that simple nasal toilet with 
saline drops and a suction bulb can signiﬁ  cantly improve 
work of breathing and frequently abort the requirement for 
mechanical ventilatory support. Infants with hypoxemia 
refractory to supplemental oxygen, persistent respiratory 
distress or progressive respiratory failure usually require 
either non-invasive support with nasal continuous positive 
airway pressure (NCPAP) or endotracheal intubation.Therapeutics and Clinical Risk Management 2008:4(5) 897
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Infants with bronchiolitis have decreased nutritional 
intake due to respiratory distress and tachypnea, which 
puts these patients at increased risk of aspiration and may 
therefore warrant the suspension of oral feeding. In addition, 
insensible losses are increased because of fever and elevated 
work of breathing. Adequate ﬂ  uid intake and nutrition should 
be maintained with parenteral ﬂ  uids or with placement of a 
nasogastric or orogastric feeding tube.
Pharmacological interventions
Bronchodilators
Bronchodilators are frequently tried in infants presenting 
with wheezing due to bronchiolitis because of its similarity 
to asthma. Their routine use is controversial. Despite many 
randomized, controlled trials (RCT), no consistent beneﬁ  t 
has been demonstrated. It is probably sensible to give a brief 
trial of bronchodilators to patients with bronchiolitis while 
the effect is carefully monitored, but their use should be 
continued only if clinical improvement can be documented 
by objective endpoints.
Albuterol
A number of small RCTs have evaluated the effectiveness of 
albuterol in the treatment of acute bronchiolitis, with conﬂ  ict-
ing results. A double-blind, placebo-controlled trial evaluated 
the efﬁ  cacy of nebulized albuterol in the treatment of infants 
aged 0–24 months with wheezing (Schweich et al 1992). 
Twenty-ﬁ  ve infants were randomized to receive nebulized 
albuterol or saline placebo. The infants were assessed after 
each treatment for wheeze, retractions score, respiratory rate, 
heart rate, and pulse oximetry. In this study, the authors were 
able to demonstrate signiﬁ  cant improvement in the wheeze 
and oxygenation scores of those infants that received alb-
uterol, while no signiﬁ  cant difference in the heart rate and 
respiratory rate were noted. These ﬁ  ndings are supported 
by a Canadian double-blind, placebo-controlled trial that 
evaluated 40 infants between 6 weeks and 24 months of age 
with a ﬁ  rst episode of wheezing and signs and symptoms of 
bronchiolitis (Schuh et al 1990). Improvements were dem-
onstrated in oxygenation and work of breathing after two 
doses of albuterol. A criticism of both of these studies is 
that the patients were not followed over time, and no effect 
was demonstrated in improved resolution of symptoms or 
in length of stay (LOS). In fact, several other studies have 
shown opposite results, suggesting that albuterol offers no 
consistent improvement in patients with bronchiolitis.
Gadomski et al (1994) evaluated 88 infants with the ﬁ  rst 
episode of wheezing in an emergency department setting. 
The subjects were randomized to receive two nebulized 
albuterol or nebulized placebo treatments 30 minutes apart 
or a single dose of oral albuterol or saline placebo. The 
investigators measured respiratory rate, heart rate, clinical 
scores, oxygen saturations and level of wakefulness. No sig-
niﬁ  cant difference was demonstrated among the four groups. 
Klassen et al (1991) demonstrated a short-term improvement 
in clinical scores 30 minutes after a single albuterol treat-
ment; however no difference was demonstrated 60 minutes 
after the treatment. There was no difference between the two 
groups when oxygenation was compared.
Inpatient trials have also failed to demonstrate beneﬁ  t in 
patients receiving nebulized albuterol. A small RCT evalu-
ated 52 hospitalized infants with moderately severe acute viral 
bronchiolitis (Dobson et al 1998). There was no improvement 
in oxygenation, time to meet discharge criteria, or length 
of stay. A 1992 meta-analysis of 8 clinical trials examined 
several outcomes (Flores and Horwitz 1997). The analysis 
was unable to demonstrate any impact on the hospitalization 
rate or respiratory rate. The authors did ﬁ  nd a statistically sig-
niﬁ  cant, but clinically insigniﬁ  cant, improvement in oxygen 
saturation and heart rate. They concluded that evidence for the 
efﬁ  cacy of β2-agonist therapy in bronchiolitis is lacking.
In summary, albuterol has not been shown to consistently 
reduce the duration or severity of illness or length of hospital 
stay, and so cannot be recommended for routine care of the 
patient with bronchiolitis. A carefully monitored trial in 
individual patients may be warranted, with discontinuation 
of therapy if no improvement is noted. Animal model studies 
suggesting that single-isomer preparations like levalbuterol 
may have a better anti-inﬂ  ammatory effect than racemic 
albuterol in RSV-infected airways (Auais et al 2005) have 
yet to be conﬁ  rmed in clinical trials.
Racemic epinephrine
As with albuterol, the use of nebulized racemic epinephrine is 
controversial. No strong evidence exists to support its routine 
use; nevertheless, it is frequently used in wheezing infants 
with bronchiolitis. In a small, placebo-controlled, randomized 
trial, Kristjansson et al (1993) demonstrated an improvement 
in oxygen saturations at 30, 45 and 60 minutes after inhalation 
of nebulized epinephrine. However, the authors were unable 
to show that these responses improved the overall course. 
A small, non-controlled trial investigated the use of nebulized 
l-epinephrine in intubated infants with bronchiolitis, showing 
a signiﬁ  cant reduction in airway resistance after treatment 
with nebulized epinephrine (Numa et al 2001). Despite this, 
there was no reduction in oxygen requirement.Therapeutics and Clinical Risk Management 2008:4(5) 898
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More recently, a large RCT compared nebulized 
epinephrine with placebo in 194 infants hospitalized with 
bronchiolitis (Wainwright et al 2003). Patients were ran-
domized to receive 3 doses of nebulized epinephrine or 
placebo, 4 hours apart. The authors evaluated length of stay, 
respiratory and heart rates, work of breathing, and length of 
oxygen therapy, and, again, found no signiﬁ  cant reduction 
in the measured outcomes.
Several studies have compared the efﬁ  cacy of nebulized 
albuterol against epinephrine. In one such study, Menon 
et al (1995) compared nebulized epinephrine to albuterol 
in an emergency department setting. Of those patients who 
received nebulized epinephrine, 33% required hospital 
admission compared with 81% of the albuterol group. In 
this study, the authors conclude that nebulized epinephrine 
is more effective than albuterol in preventing hospitalization 
of infants with bronchiolitis. In another evaluation of the 
efﬁ  cacy of nebulized epinephrine versus albuterol, Hartling 
et al (2003) conducted a meta-analysis of 14 available stud-
ies. Among outpatients, epinephrine was more effective 
than albuterol or placebo in the reduction of clinical score, 
improvement in oxygenation and respiratory rates, and 
overall improvement. The measured outcomes also indicated 
that epinephrine was more effective in the inpatient setting, 
with improvements in clinical score and respiratory rate. 
However, in 2004 a Cochrane report of the available data 
found a lack of evidence to support the use of epinephrine 
in the inpatient setting (Hartling et al 2004). The report also 
determined that among outpatients, epinephrine may be more 
favorable than albuterol.
While no strong evidence exists to support the routine 
use of albuterol or epinephrine, the use of bronchodilators in 
select patients seems reasonable. When a bronchodilator trial 
is given, the available data supports the use of epinephrine 
over albuterol. If clinical improvement can be documented, 
then continued use is indicated. However, treatments should 
be discontinued if no improvement can be demonstrated. As 
epinephrine is typically not prescribed for use at home, alb-
uterol may be a more appropriate choice for outpatient use.
Anticholinergic agents
Anticholinergic agents such as ipratropium bromide have not 
been demonstrated to be effective in the treatment of bronchi-
olitis. Several studies have evaluated ipratropium alone and 
with albuterol. While minor improvements in oxygenation 
have been reported, there is no consistent, signiﬁ  cant beneﬁ  t 
to the overall clinical course or outcome (Wang et al 1992; 
Chowdhury et al 1995; Schuh et al 2002).
Corticosteroids
Corticosteroids are commonly used in the treatment of 
bronchiolitis as anti-inﬂ  ammatory agents; their use may be 
as high as 60% of inpatient therapy (Bronchiolitis 2006). 
Their appeal may be due to the similarities of bronchiolitis 
to asthma and to the role that corticosteroids play at many 
intracellular levels to reduce inﬂ  ammation. In theory, corti-
costeroids should be of beneﬁ  t in reducing the inﬂ  ammatory 
response of the lower airways against viral infections, and for 
this reason they have been widely prescribed by physicians. 
But in reality, several studies and meta-analyses with corti-
costeroids have failed to show any signiﬁ  cant beneﬁ  t in acute 
or long-term clinical outcomes of virus-induced wheezing, 
whether administered systemically or inhaled.
Systemic corticosteroids
Bulow et al investigated the short and long term effects of 
systemic corticosteroids in infants admitted with RSV bron-
chiolitis (Bulow et al 1999). One hundred and forty-seven 
hospitalized infants were randomized to receive 2 mg/kg/day 
prednisolone or placebo for 5 days. Outcomes measured 
included length of stay and use of adjunctive medications and 
supportive therapies while hospitalized, as well as at 1 month 
and 1 year follow up. This study found no evidence that 
prednisolone effected any of the outcome measures. Schuh 
et al evaluated 70 children under the age of 2 years presenting 
to the emergency department with moderate or severe acute 
bronchiolitis (Schuh et al 2002). The patients were randomized 
to receive 1 mg/kg of oral dexamethasone vs placebo, and 
were evaluated hourly for 4 hours. Each group also received 
nebulized albuterol at 0, 30, 60, and 120 minutes. The authors 
demonstrated a greater rate of clinical improvement among 
the dexamethasone group, to such extent that there was a 
decrease in the admission rate (19% vs 44%) compared with 
the placebo group.
In a more recent study conducted in Thailand, 
Teeratakulpisarn et al (2007) evaluated 174 children hospital-
ized with acute bronchiolitis. The children were randomized 
to received 0.6 mg/kg of intramuscular dexamethasone or 
placebo. The authors evaluated the length of time to reso-
lution of respiratory distress as the primary outcome. The 
duration of respiratory distress was decreased from 39 hours 
for the placebo group to 27.2 hours for the dexamethasone 
group, a difference of about 12 hours. The duration of oxygen 
was also reduced by 14.9 hours, and the hospital LOS was 
decreased by 13.4 hours.
Two meta-analyses are also available. Garrison et al 
(2000) evaluated 6 studies with a combined total of Therapeutics and Clinical Risk Management 2008:4(5) 899
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347 subjects. The outcomes measured included LOS and 
impact on severity of symptoms. The authors reported statisti-
cally signiﬁ  cant reductions in clinical symptom scores and a 
reduction in LOS of 0.43 hospital days/patient. These num-
bers are similar to those reported by Teeratakulpisarn et al. 
Although the reduction of hospitalization by half a day would 
not be clinically signiﬁ  cant for the individual patient, the 
authors argue that approximately 51,000 hospital days could 
be saved annually by the routine use of corticosteroids.
Patel et al conducted a larger systematic review of 
13 trials of glucocorticoid therapy in 1198 children with viral 
wheezing aged 0–30 months (Patel et al 2004). They found a 
similar decrease in LOS of 0.38 hospital days/patient, which 
however was not statistically signiﬁ  cant. There was no differ-
ence in clinical scores, respiratory rate or oxygen saturation. 
For patients treated in the emergency department or clinic, 
there was no difference in admission rates. The authors do 
caution that signiﬁ  cant heterogeneity of the included stud-
ies and results make the ﬁ  nal analysis difﬁ  cult to interpret 
with conﬁ  dence, but concluded that this therapy lacks any 
signiﬁ  cant clinical beneﬁ  t compared to placebo and is not 
of beneﬁ  t for this patient group.
In a more recent double blind, randomized trial, Corneli 
et al (2007) compared oral dexamethasone with placebo to 
study whether a single dose of oral dexamethasone (1 mg/kg) 
could reduce the need for hospitalization. Over a 3-year 
period, the authors enrolled 600 infants between the ages of 
2 and 12 months presenting to the emergency department 
with ﬁ  rst-time wheezing and a diagnosis of moderate-severe 
bronchiolitis. The primary outcome was hospital admission 
after 4 hours of emergency department observation. Sec-
ondary and later outcomes measured included: change in a 
respiratory assessment score, length of hospital admission, 
later medical visits or hospital admissions and adverse events. 
The authors found that a single dose of dexamethasone did 
not change the rate of hospital admission or the severity score 
of bronchiolitis after 4 hours. They also found no change in 
later outcomes.
Inhaled corticosteroids
Several studies have evaluated inhaled corticosteroids in 
patients with bronchiolitis, but no consistent beneﬁ  t has 
been demonstrated (de Blic 2001; Chao et al 2003). A recent 
RCT compared 61 infants randomized to receive nebulized 
dexamethasone or saline; both groups also received nebulized 
epinephrine (Bentur et al 2005). In this study, no statistically 
signiﬁ  cant difference was noted in clinical score or oxygen 
saturation. There was, however, a signiﬁ  cant reduction in 
LOS in the dexamethasone group, especially among the 
subgroup of prematurely born infants (6.5 ± 1.7 days vs 
9.1 ± 1.9 days).
In a Cochrane review of 5 studies with a total of 374 
infants, Blom et al (2007) evaluated the use of inhaled 
corticosteroids to prevent post-bronchiolitic wheezing. 
This analysis demonstrated no reduction of wheezing, 
readmission rate, use of systemic corticosteroids or use of 
bronchodilators.
In general, young children without an atopic phenotype 
that wheeze in response to viral infections show a poor 
response to corticosteroids, and even children that will 
ultimately develop asthma are usually unresponsive to this 
therapy when they develop virus-induced wheezing during 
their ﬁ  rst years of life. Another area of concern derives from 
safety considerations. In fact, severe RSV bronchiolitis typi-
cally occurs during the ﬁ  rst year of life and coincides with a 
critical phase of rapid lung development. The safety of the 
therapeutic use of corticosteroids during this window, par-
ticularly at high doses and for prolonged periods, is virtually 
unknown and consequently no steroid has ever been approved 
by the US FDA for use in the ﬁ  rst year of life.
We conclude that whether administered systemically or 
inhaled, corticosteroids should not be routinely used in the 
treatment of bronchiolitis. However, some speciﬁ  c patient 
populations may beneﬁ  t from a trial of steroid therapy, 
particularly patients with family history (parental atopy or 
asthma) or medical history (atopic eczema) suggestive of 
atopic predisposition.
Ribavirin
Ribavirin is a synthetic nucleoside analog that demonstrates 
good in vitro activity against RSV. Several factors make its 
routine use controversial: it is expensive, difﬁ  cult to admin-
ister, and possibly a teratogen. Furthermore, the available 
studies are all small, have inconsistent quality, and have 
produced conﬂ  icting results.
Early studies were encouraging. In 1983, Hall et al (1983) 
randomized 33 infants hospitalized with RSV to continuous 
aerosolized ribavirin for 3–6 days versus placebo. The riba-
virin group demonstrated a greater improvement in severity 
score, lower respiratory tract signs, oxygen saturations and 
viral shedding compared to the placebo group. Rodriguez 
et al (1987) also demonstrated improved oxygenation and 
a greater rate of clinical improvement in patients receiving 
a short course of ribavirin, without evidence of adverse 
effects. Smith et al (1991) conducted a double-blind, 
placebo-controlled trial of continuously aerosolized ribavirin Therapeutics and Clinical Risk Management 2008:4(5) 900
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in 28 mechanically ventilated infants with RSV infection, 
using nebulized sterile water as a control. This study reported 
a signiﬁ  cant reduction in oxygen use and in the length of 
mechanical ventilation and hospitalization, especially among 
infants with no underlying illness, but these ﬁ  ndings were 
criticized because bronchospasm associated with sterile 
water nebulization may artiﬁ  cially make ribavirin seem 
more effective (Moler et al 1991).
A subsequent, well-designed study evaluated ribavirin 
against nebulized saline in 42 mechanically ventilated 
patients with RSV bronchiolitis and respiratory failure 
(Guerguerian et al 1999). The authors found no signiﬁ  cant 
improvement in the length of oxygen therapy, aerosol 
therapy, mechanical ventilation, PICU stay, or hospital stay. 
These ﬁ  ndings were supported by a similar study performed 
by Meert et al (1994). Taber et al (1983) evaluated 26 infants 
randomized to receive ribavirin or placebo and found no 
difference in the rate of viral clearance between the two 
groups. In a longer outcome study, Everard et al (2001) fol-
lowed patients treated with ribavirin for RSV bronchiolitis 
over 1 year and was unable to demonstrate any short-term 
improvement in the clinical course or long-term reduction 
in the use of inhaled bronchodilators or steroids.
In the early 1990s, the AAP endorsed ribavirin use for 
RSV bronchiolitis. This stance has since changed and the 
current recommendation is that ribavirin should not be 
used routinely to treat children with bronchiolitis. It should, 
however, be considered to treat RSV infection in immuno-
compromised hosts (Bronchiolitis 2006).
Antibiotics
It is not uncommon for infants with bronchiolitis to receive 
antibiotic therapy. It is estimated that antibiotics are used 
in 34%–99% of uncomplicated bronchiolitis (Kabir et al 
2003; Vogel et al 2003). This therapy is frequently started 
because the patient is febrile, but fever per se cannot reli-
ably differentiate viral from bacterial infections (Putto et al 
1986). In fact, the risk of bacterial superinfection in infants 
with bronchiolitis and fever is quite low (0.2%), even when 
the temperature is 39 °C (Willwerth et al 2006). For intu-
bated infants with severe bronchiolitis, the rate of secondary 
bacterial infection is much higher, and may be as high as 
26% (Spurling et al 2007).
When a secondary bacterial infection (SBI) is diagnosed, 
the most common sites are the urinary tract and the middle 
ear (Andrade et al 1998; Purcell and Fergie 2004). In par-
ticular, infants with SBI are more likely to have a urinary 
tract infection than bacteremia or meningitis (12% vs 0.43%) 
(Purcell and Fergie 2004). Acute otitis media (AOM) is also 
seen as a complication of RSV infection (57%–67%), but its 
presence does not seem to inﬂ  uence the severity of fever, 
respiratory distress, or the overall clinical course of the dis-
ease (Shazberg et al 2000). In one series, evaluation of middle 
ear aspirates in children with bronchiolitis revealed RSV in 
17 (71%) of 24 patients (Andrade et al 1998). In addition, 
all patients with acute otitis media had bacterial pathogens 
isolated, the most common being Streptococcus pneumoniae, 
Haemophilus inﬂ  uenzae, and Moraxella catarrhalis. If pres-
ent, AOM should be managed according to current AAP 
recommendations (AOM 2004; Bronchiolitis 2006).
Several prospective RCTs have evaluated the clinical 
outcomes of infants who received antibiotics for the manage-
ment of bronchiolitis. As early as 1966, a double blind RCT 
failed to demonstrate a beneﬁ  t to treating bronchiolitis with 
antibiotics (Field et al 1966). Friis et al (1984) evaluated 
136 children between the ages of 1 month and 6 years and 
found no difference in the course of the acute illness, fever 
relapse, or pulmonary complications in those patients with 
bronchiolitis who received antibiotics compared with those 
who did not (Friis et al 1984).
We conclude that antibiotics should be used in patients 
with bronchiolitis only when speciﬁ  c evidence of coexistent 
bacterial infection is present and conﬁ  rmed bacterial infec-
tions should be managed no differently than in the absence 
of bronchiolitis.
Surfactant
Beyond its role of decreasing surface tension in alveoli and 
bronchioles, thereby improving alveolar and small airway 
patency, surfactant has protein components (A and D) that 
bind viral and bacterial surface markers and facilitate their 
immune-mediated elimination (Ventre et al 2006). In addi-
tion, surfactant protein D has been demonstrated to promote 
alveolar macrophage production of free radicals (LeVine et al 
2004). In acute bronchiolitis, there is decreased production of 
these surfactant proteins, which return to normal levels with 
the resolution of the illness (Dargaville et al 1996).
Administration of exogenous surfactant to infants with 
severe respiratory failure due to bronchiolitis seems promis-
ing. Several small RCTs have been conducted to evaluate 
this therapy, with encouraging results. A recent meta-analysis 
by Ventre et al (2006) included 3 studies with a total of 
79 patients. The authors identify decreases in duration of 
mechanical ventilation and PICU stay. There also seem to be 
improvements in pulmonary mechanics and gas exchange. 
It is important to note that the available studies are small Therapeutics and Clinical Risk Management 2008:4(5) 901
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and underpowered, and that additional studies are required. 
However, exogenous surfactant therapy does appear to hold 
promise for use in patients with severe respiratory failure 
due to bronchiolitis.
Heliox
Medical helium for the treatment of upper airway obstruc-
tion and asthma was ﬁ  rst described by Barach in the 1930s 
(Barach and Eckman 1936). Heliox is a mixture of helium 
and oxygen in a 70:30 or 80:20 ratio that maintains greater 
laminar ﬂ  ow and less turbulence through constricted airways 
than does nitrogen-oxygen mixtures. This reduces work of 
breathing and improves ventilation in patients with lower 
respiratory tract disease. Heliox has been studied in the treat-
ment of bronchiolitis by several investigators, although most 
of these studies are quite small. Some of the authors have 
shown small improvements in clinical scores and decreased 
tachypnea and work of breathing (Hollman et al 1998; 
Martinon-Torres et al 2002; Cambonie et al 2006).
Liet et al (2005) evaluated rates of positive pressure 
ventilation in patients receiving heliox therapy vs standard 
nitrogen-oxygen air and found no difference between the 
two groups. When heliox therapy was evaluated in intubated 
children with bronchiolitis, Gross et al found no improve-
ment in ventilation or oxygenation, regardless of the ratio of 
helium to oxygen employed (50:50, 60:40, or 70:30) (Gross 
et al 2000).
Heliox equipment is bulky and cumbersome and it can 
be problematic to administer. Furthermore, given that it is 
most effective at high helium to oxygen ratios, it is minimally 
effective in patients with higher oxygen requirements. In 
summary, the current evidence supporting heliox use for 
bronchiolitis is sparse, underpowered and conﬂ  icting, and 
therefore larger RCTs are required before it can be recom-
mended for routine use.
Summary
Bronchiolitis is a common lower respiratory tract infection in 
infants caused by viral agents, the most common of which is 
RSV. Despite numerous attempts to identify pharmacological 
therapies to improve the clinical course and outcomes of this 
disease, the most effective therapy remains supportive care. 
Careful attention should be focused on maintaining patency 
of the infant’s airway with gentle nasal and pulmonary toilet. 
Supplemental humidiﬁ  ed oxygen is frequently required to 
maintain oxygen saturations above 92%. Patients should 
be monitored to ensure adequate ﬂ  uid and nutrition intake, 
which may require supplementation with naso-gastric feeds 
or intravenous ﬂ  uids. Bronchodilators are not consistently 
effective, but may have some beneﬁ  t in selected patients. If 
given to patients with bronchiolitis, their use should only be 
continued if objective measures demonstrate improvement in 
the patients oxygenation or work of breathing. Corticosteroids 
have not been shown to be effective and are not recommended 
for routine use. Ribavirin is not recommended for routine use 
in patients with bronchiolitis, although it may be of beneﬁ  t 
in immunocompromised patients. Antibiotics should only 
be used in the presence of a conﬁ  rmed bacterial infection. 
Surfactant and heliox therapies may be tried for the treatment 
of severe respiratory failure, although additional studies are 
needed before they can be recommended for routine use.
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